Atypical Antipsychotics in Children with Pervasive Developmental Disorders

@article{Chavez2007AtypicalAI,
  title={Atypical Antipsychotics in Children with Pervasive Developmental Disorders},
  author={Benjamin Chavez and Mapy Ch{\'a}vez-Brown and Michael A Sopko and Jos{\'e} Antonio Ortiz Rey},
  journal={Pediatric Drugs},
  year={2007},
  volume={9},
  pages={249-266}
}
The treatment of pervasive developmental disorders (PDDs) is a challenging task, which should include behavioral therapy modifications as well as pharmacologic therapy. There has been a lack of data on using medications in children with PDDs until recent years. Within the last 10 years, an increase in clinical research has attempted to provide efficacy and safety data to support the use of medications in children with PDDs. Double-blinded and open-label research of atypical antipsychotics has… Expand
Prescribing antipsychotics for children and adolescents
TLDR
Evidence from an increasing number of randomised controlled trials (RCTs) points to therapeutic efficacy with moderate to large effect sizes, however, some RCTs have a small number of participants, are of short duration, and many are industry funded. Expand
[Acute Dystonia due to Aripiprazole Use in Two Children with Autism Spectrum Disorder in the First Five Years of Life].
TLDR
A review of the literature uncovered limited data regarding the association between acute dystonia and aripiprazole use in ASD children under five years of age, and presented two cases of autistic spectrum disorder children with ages under 5 years that developed acute Dystonia taking aripipsine. Expand
Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis.
  • Akanksha Sharma, S. Shaw
  • Psychology, Medicine
  • Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
  • 2012
TLDR
Outcome measures demonstrated mean improvement in problematic behaviors equaling one standard deviation, and thus current evidence supports the effectiveness of risperidone in managing behavioral problems and symptoms for children with ASD. Expand
Atypical and Typical Antipsychotics in the Schools.
The use of antipsychotic medications within the school-age population is rapidly increasing. Although typical antipsychotics may be used in rare cases, this influx is largely secondary to theExpand
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children
  • E. Kirino
  • Medicine
  • Clinical medicine insights. Pediatrics
  • 2014
TLDR
Head-to-head comparison studies are needed to support that aripiprazole may be a promising drug that can be used to treat irritability in autistic children, and risperidone has the greatest amount of evidence supporting it, including randomized controlled trials; thus, its efficacy and tolerance has been established in comparison with other agents. Expand
Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents.
TLDR
Oral risperidone treatment was better than placebo treatment in reducing irritability and other behavioral symptoms associated with autistic disorder in children and adolescents in two well designed short-term trials, with these benefits maintained in those receiving ris peridone for up to 6 months. Expand
Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders.
A utism spectrum disorders (ASD) are pervasive neurodevelopmental disorders affecting approximately 1% of children and characterized by varying degrees of deficiencies in social interactions,Expand
Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive Behavior: Open-Label Trial
TLDR
Short-term low-dose quetiapine treatment may reduce aggression levels and improve sleep quality in adolescents with ASD. Expand
Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders.
TLDR
An open-label study of aripiprazole in youth with ASDs over a 12 week period, to test its effectiveness and safety in youth 7–14 years of age and confirmed using both the Autismdiagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R). Expand
Acute and long-term safety and tolerability of risperidone in children with autism.
TLDR
Most AEs were mild to moderate and failed to interfere with therapeutic changes; there were no unanticipated AEs; the side effects of most concern were somnolence and weight gain. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 144 REFERENCES
Risperidone in children with autism and serious behavioral problems.
TLDR
Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months. Expand
Psychiatry: Role of Risperidone in Children with Autism Spectrum Disorder
TLDR
Based on the data examined, risperidone appears efficacious and safe for treating certain behavioral aspects of autism including irritability, aggression, hyperactivity, and stereotypy, but does not appear to be as effective for the treatment of the core symptoms of autism. Expand
Use of risperidone in pervasive developmental disorders: a case series.
  • S. Fisman, M. Steele
  • Psychology, Medicine
  • Journal of child and adolescent psychopharmacology
  • 1996
TLDR
Positive and negative symptoms, as typically characterized in schizophrenia, were both found to improve equally well with risperidone treatment, and a prospective clinical trial with a randomized controlled design is warranted. Expand
Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders
TLDR
Risperidone was well tolerated and efficacious in treating behavioral symptoms associated with PDD in children and seemed manageable with dose/dose-schedule modification. Expand
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
TLDR
Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern. Expand
Atypical antipsychotics in persons with developmental disabilities
The introduction of clozapine spawned the development of several novel antipsychotic agents during the last decade. Compared to traditional agents, these “atypical antipsychotics” demonstrate moreExpand
Risperidone in pervasive developmental disorders
TLDR
This drug profile will review the available data on the use of risperidone in individuals with pervasive developmental disorders and emphasis will be placed on adverse effects associated with risperide in these people. Expand
Genetics of childhood disorders: XLIV. autism, part 3: psychopharmacology of autism.
  • C. McDougle, D. Posey
  • Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2002
TLDR
The pharmacological management of hyperactivity and impaired attention has proven particularly challenging and lithium, valproic acid, carbamazepine, and gabapentin, have not been reported in well-defined groups of autistic subjects. Expand
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
TLDR
The data indicate that risperidone is an effective and relatively safe drug for long term treatment of behavioral disruption in autistic children and adolescents. Expand
Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
TLDR
Risperidone shows promise as a treatment in autism, however, withdrawal dyskinesias were noted and the need for further drug treatment and the occurrence of withdrawal Dyskinesia were assessed. Expand
...
1
2
3
4
5
...